Abstract | BACKGROUND AND PURPOSE: MATERIALS AND METHODS: A 66-year-old male with unresectable locally advanced PDAC was enrolled on our clinical trial to receive NBTXR3 activated by radiation therapy. Local endoscopic delivery of NBTXR3 was followed by intensity modulated radiation therapy (IMRT). Follow-up assessment consisted of physical examination, laboratory studies including CA19-9, and CT of the chest, abdomen, and pelvis. RESULTS: The patient received NBTXR3 by local endoscopic delivery without any acute adverse events. Radiation treatment consisted of 45 Gy in 15 daily fractions using IMRT. The patient began radiation twelve days after NBTXR3 injection. Daily CT-on-rails imaging demonstrated retention of NBTXR3 within the tumor for the duration of treatment. At initial follow-up evaluation, the lesion remained radiographically stable and the patient did not demonstrate treatment-related toxicity. CONCLUSION: This report demonstrates initial feasibility of local endoscopic delivery of NBTXR3 activated by radiation therapy for patients with pancreatic cancer who are not eligible for surgery.
|
Authors | Alexander F Bagley, Ethan B Ludmir, Anirban Maitra, Bruce D Minsky, Grace Li Smith, Prajnan Das, Albert C Koong, Emma B Holliday, Cullen M Taniguchi, Matthew H G Katz, Eric P Tamm, Robert A Wolff, Michael J Overman, Shivani Patel, Michael P Kim, Ching-Wei D Tzeng, Naruhiko Ikoma, Manoop S Bhutani, Eugene J Koay |
Journal | Clinical and translational radiation oncology
(Clin Transl Radiat Oncol)
Vol. 33
Pg. 66-69
(Mar 2022)
ISSN: 2405-6308 [Electronic] Ireland |
PMID | 35097226
(Publication Type: Case Reports)
|
Copyright | © 2022 The Authors. |